Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance
about
Concordant and opposite roles of DNA-PK and the "facilitator of chromatin transcription" (FACT) in DNA repair, apoptosis and necrosis after cisplatin6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancersBRCAness: finding the Achilles heel in ovarian cancerFOXM1 confers acquired cisplatin resistance in breast cancer cellsHigh sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsCytotoxic and targeted therapy for hereditary cancersRole of Biomarkers in the Development of PARP InhibitorsThe Landscape of Pancreatic Cancer Therapeutic Resistance MechanismsOvarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a ChallengeHomologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian CancerPARP inhibitors in the management of breast cancer: current data and future prospectsGenomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancersEvolution of the cancer genomeTargeting DNA damage response in cancer therapyPARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignanciesFine tuning chemotherapy to match BRCA1 statusGermline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomasRole of DNA repair machinery and p53 in the testicular germ cell cancer: a reviewPathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancerVeliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair.Next-generation sequencing.Genome-wide transcriptome profiling of homologous recombination DNA repair.A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy.Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancerSublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells.A global profile of gene promoter methylation in treatment-naïve urothelial cancerPrediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins.Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms.Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers.BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma.BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma.Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer.Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer.Down-regulation of Ras-related protein Rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines.Pathogenesis of serous, extra-uterine Müllerian epithelial cancer and therapeutic implicationsBRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.
P2860
Q24306623-8069D00F-747B-4A23-A310-4CD9CD7A264FQ24599364-4482240B-3DFA-4B72-A32D-590E22393822Q24600350-E5758B18-6758-4F15-ADE0-3F647E9AEE42Q24630872-D854C545-AEBB-4137-9397-CCE0677F3C8EQ24642596-F2F4F93F-AC96-4D98-8546-460E8F228CDDQ24644255-BE2674DE-6D49-4E1A-A4AA-BDBDD2812CBFQ26739366-2A9D32AE-E7A0-4286-81C6-DDC4870A2F39Q26753159-1E278C2C-D7DE-4273-8AF9-B2F16A8988FCQ26765247-D33D7554-84F2-4325-B778-915BF55A0C64Q26777846-73B217A6-2BCA-489D-99C8-B7C69AEC10F0Q26783551-DCC972B0-AB1D-46CA-9586-3C3517D40A31Q26798352-4C4A24AF-97E9-4BDC-BEB5-6289742A6E8FQ27006938-7E323E46-BC29-45B1-9EB4-677C9BD2955CQ27020991-077172F6-0059-4EB2-83FB-D8B81BFBCDBDQ27023204-4B2E2200-87C2-4F36-9871-07D71F7737A4Q27027503-95F71EEC-952C-47D9-B4B1-B8149E243B47Q27694529-65813ACD-9E6B-42FC-943C-B01A01620DD9Q27852671-17BA33B9-F92B-4DFD-A915-9D473C873E37Q28069963-839E8CE0-839B-4BBE-9CCF-56A5725FB7C5Q28538059-CCEF5FEB-66A1-4B2E-BCD0-B1E7BC1F6226Q33429801-7F746328-5DDE-4431-A347-F7827AD4FDCCQ33555502-6E65529C-BF6A-42F3-97FA-782F62300870Q33598112-E6B6BE75-4F7C-4691-85EC-88D2C64B797EQ33698648-C4B10CAE-AF2D-4509-AB2E-C43D61072F94Q33704050-708B5D48-EF19-4B1E-842D-7273D3D4F8AAQ33757073-9956D991-5D50-4577-9A52-38F922CA0761Q33779194-0934F754-562C-40AD-997D-9DD4D354AA8BQ33889482-6A0D32A6-8E7B-43F3-87EB-2582F421B62DQ33889555-DBBC7567-5774-4F2D-8E0F-598B09B9AE04Q33917649-E7157C5B-8130-47DA-ACD2-71E722F8A357Q33930051-B1085E6C-4BED-4CFC-A328-C06305CA6FB8Q33944203-57D913DB-7C61-4DDB-BD6F-62CA90E45A76Q34049228-4B30F9B8-7158-497C-B142-6AC3584F3871Q34104724-60F3B2A0-736D-48CA-9BC4-EC9A90DFD246Q34134454-F3B0EA30-CC21-49F5-9796-A77F406281ACQ34168535-567A52B6-E157-4E81-9F52-CACB866E71CDQ34305493-3746D01F-FA04-4960-A6E6-97BD81BD5CF0Q34468400-2E11D476-9A9C-4B9F-A436-6EA84F9B9713Q34501822-8D36DF12-55A9-47D7-9E61-2E5AD18B061AQ34539782-75C78DA6-43BF-4B15-A8B1-B5EEFEA86BAB
P2860
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance
@en
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.
@nl
type
label
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance
@en
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.
@nl
prefLabel
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance
@en
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.
@nl
P2093
P2860
P1433
P1476
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance
@en
P2093
Beth Y Karlan
Elizabeth M Swisher
Kaitlyn Wurz
Nicole Urban
Toshiyasu Taniguchi
Wataru Sakai
P2860
P304
P356
10.1158/0008-5472.CAN-08-0088
P407
P577
2008-04-01T00:00:00Z